8-K: Hillenbrand to Sell Majority Stake in Milacron Injection Molding Business to Bain Capital Affiliate for $287 Million

Hillenbrand, Inc. will sell majority ownership of its Milacron injection molding and extrusion business to BCSS Iota (A), LLC, an affiliate of Bain Capital Special Situations, LP, for $287 million in cash while retaining a 49% equity interest.

Summary

• Hillenbrand, Inc. has entered into an agreement to sell a majority stake in its Milacron injection molding and extrusion business to BCSS Iota (A), LLC, an affiliate of Bain Capital Special Situations, LP.
• Under the agreement, Hillenbrand will undergo internal restructuring to contribute the Milacron business to a newly formed entity (HoldCo).
• Purchaser will acquire majority ownership and full operational control of the Milacron Business.
• Hillenbrand will receive $287 million in cash, subject to adjustments, and retain an approximately 49% equity interest in HoldCo.
• Holdco will enter into a management agreement with a Bain affiliate for ongoing management services with an annual retainer fee.
• The transaction is subject to customary closing conditions, including antitrust approvals, accuracy of representations and warranties, compliance with obligations, completion of the reorganization, and absence of a Material Adverse Effect.
• The agreement includes customary termination provisions, including a termination date of July 28, 2025.
• Bain has provided a guarantee to Hillenbrand for the payment of the termination fee and certain other obligations of Purchaser.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Hillenbrand is receiving a significant cash infusion and retaining a stake in the business, while Bain Capital's involvement could bring operational improvements. However, there are risks associated with the transaction and the loss of control over the Milacron Business.

Positives

• Hillenbrand will receive $287 million in cash from the sale.
• Hillenbrand retains a 49% equity interest in HoldCo, allowing them to benefit from future growth.
• Bain Capital's involvement could bring operational expertise and resources to the Milacron Business.

Negatives

• Hillenbrand is giving up majority ownership and operational control of the Milacron Business.
• The $287 million purchase price is subject to adjustments, which could reduce the final amount received.
• The transaction is subject to customary closing conditions, and there is no guarantee that it will be completed.

Risks

• The transaction is subject to regulatory approvals, including antitrust laws.
• The accuracy of representations and warranties made by both parties is a condition of closing.
• A Material Adverse Effect on the Milacron Business could prevent the transaction from closing.
• The management agreement with Bain could result in additional costs for HoldCo.

Future Outlook

The closing of the transaction is subject to customary conditions and is expected to occur by July 28, 2025.

Industry Context

The sale of Milacron reflects a strategic decision by Hillenbrand to focus on other areas of its business. Private equity firms like Bain Capital are actively investing in industrial businesses, seeking to improve operations and drive growth.

Comparison to Industry Standards

• Comparable transactions in the plastics and industrial sectors often involve strategic buyers or private equity firms.
• The valuation metrics for this deal (e.g., revenue multiples, EBITDA multiples) will be closely watched by industry analysts to assess its fairness.
• Similar companies that have been acquired or divested include Husky Injection Molding Systems (acquired by Platinum Equity) and KraussMaffei (owned by ChemChina).

Stakeholder Impact

• Shareholders: May react positively to the cash infusion and strategic shift.
• Employees of Milacron: May experience changes under new ownership and management.
• Customers and Suppliers: May see changes in operations and relationships.

Next Steps

• Obtain regulatory approvals, including antitrust clearance.
• Complete the internal restructuring steps (Reorganization).
• Satisfy all other customary closing conditions.
• Close the transaction by July 28, 2025.

Key Dates